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Abstract The effects of etomoxir, an inhibitor of mitochondrial 
long-chain fatty acid oxidation, on triacylglycerol metabolism in 
rat hepatocytes and adipocytes were investigated. Etomoxir 
inhibited the depletion of triacylglycerol stores in hepatocytes 
incubated without exogenous fatty acids and inhibited lipolysis in 
adipocytes. The effects on hepatocytes could be attributed to two 
mechanisms. At low concentrations (1-10 uM) /?-etomoxir 
increased fatty acid esterification by inhibition of P-oxidation. 
This effect was specific for the /{-enantiomer and was associated 
with increased triacylglycerol secretion. At higher concentrations 
(50-100 |iM) ^5-etomoxir inhibited lipolysis and triacylglycerol 
secretion, independently of inhibition of carnitine palmitoyl-
transferase I. These effects of /W-etomoxir on triacylglycerol 
metabolism and lipolysis may contribute to the chronic 
hypolipidaemic effects of etomoxir in vivo. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The raised plasma fatty acid (FA) concentration in non-
insulin-dependent diabetes mellitus ( N I D D M ) is a contribut-
ing factor to the impaired glucose utilization by muscle and 
the increased hepatic gluconeogenesis as a result of increased 
fatty acid oxidation in these tissues [1]. This led to the devel-
opment of inhibitors of FA oxidation for the treatment of 
N I D D M . These include substituted 2-oxiranecarboxylates, 
e.g. ethyl-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate 
(etomoxir) and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carbox-
ylate (POCA, clomoxir) and methyl tetradecyl glycidate 
(TDGA, palmoxirate). The CoA esters of these compounds 
inhibit mitochondrial carnitine palmitoyltransferase (CPT) I 
activity [2]. 
The 2-oxiranecarboxylates do not affect blood glucose con-
centrations in normal man in the fed state, but are hypogly-
caemic in fasted and diabetic animals and man [3]. Their acute 
administration increases plasma [FA] [4,5], which results in a 
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delayed increase in [triacylglycerol] in the blood in starved and 
diabetic rats [5,6] but not in normal rats [5]. This triglyceride-
mia has raised questions on use of these drugs for treatment 
of N I D D M . The acute effects of 2-oxiranecarboxylates on 
plasma FA and triacylglycerol (TAG) concentrations are 
probably due to inhibition of CPT I, which increases the 
long-chain fatty acyl-CoA/long-chain fatty acyl-carnitine ratio 
in the cytoplasm, enhances re-esterification of F A to T A G [7] 
and increases hepatic secretion of very low density lipoprotein 
(VLDL) [8]. 
By contrast, chronic administration of 2-oxiranecarboxy-
lates to healthy or diabetic rats decreases plasma cholesterol 
and T A G while the [FA] remains unchanged or is slightly 
lowered [4,9-11]. The chronic lowering of plasma F A and 
cholesterol concentrations by etomoxir and other CPT I in-
hibitors was suggested to be due to the inhibition of de novo 
FA and cholesterol synthesis as 2-oxiranecarboxylates inhibit 
F A and cholesterol biosynthesis [12-14]. These effects, unlike 
the inhibition of CPT I, are not enantiomer-specific indicating 
that they are not secondary to inhibition of |3-oxidation 
[14,15]. 
In this study we report that etomoxir inhibits lipolysis in 
adipocytes and depletion of cellular T A G stores in hepato-
cytes. The latter is due to both increased F A esterification 
and inhibition of lipolysis. These effects may contribute to 
the lowering of plasma [FA] and [TAG] during chronic treat-
ment in vivo. 
2. Materials and methods 
2.1. Materials 
[2-3H]Glycerol was from Amersham International PLC (Amer-
sham, Bucks, UK). Etomoxir (R- and S-enantiomers and RS(rac)-
etomoxir) was a gift from Dr. H. Wolf, Byk Gulden Chemische Fa-
brik GmbH (Konstanz, Germany). 
2.2. Hepatocyte culture 
Hepatocytes were isolated from male Wistar rats (body wt 200-250 
g) fed ad libitum, by collagenase perfusion of the liver [15] and cul-
tured in MEM containing 5% calf serum in 24-well plates at a density 
of 6X104 cells/cm2 [16]. 
2.3. Determination of cellular and secreted triacylglycerol in 
hepatocytes 
After cell attachment (7 h) hepatocytes were cultured in serum-free 
MEM containing the concentrations of etomoxir indicated for 24 h. 
On termination of the incubation, cellular and medium TAG were 
determined as in [16] and are expressed as nmol/mg of cell protein. 
Medium was deproteinized with perchloric acid for determination of 
acetoacetate and D-3-hydroxybutyrate [17], Protein was determined as 
in [18]. 
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Table 1 
Effects of PS-etomoxir on cellular and secreted TAG in hepatocytes 
[Etomoxir] Ketones formed D-3-Hydroxybutyrate/ 
(uM) (nmol/mg protein) acetoacetate 
Triacylglycerol (nmol/mg protein) 
0.55 ±0.06 
0.44 ±0.02 
0.41 ± 0.05b 
0.39±0.06b 
0.36±0.06a 
0.35±0.05a 
Hepatocytes were incubated for 24 h with the concentrations of PS-etomoxir indicated. Ketone body (acetoacetate+3-hydroxybutyrate) formation 
is expressed as nmol/mg protein. Cellular and secreted TAG is expressed as nmol/mg protein. Cellular TAG content at start of 24 h culture was 
80 ±4 nmol/mg protein. Values are means ± S.E.M. (« = 4). Statistics: aP<0.05, hP< 0.005 relative to respective control. 
0 
1 
5 
10 
50 
00 
545 ±61 
333±51b 
323 ±53 b 
318±48b 
272±37b 
252±29a 
Secreted 
40±5 
59±9 a 
55±9 a 
52 ±9" 
29±5 a 
16±5 a 
Cellular 
48±4 
54±4 
57±6 a 
59±5 a 
59±3 a 
64±6 
Total 
88 ±9 
113±13a 
113±14a 
l l l ± 1 4 a 
87 ±8 
80±9 
2.4. Incorporation of [2-3H]glycerol into cellular and secreted 
triacylglycerol 
After culture in serum-free MEM for 14-18 h the hepatocytes were 
incubated for 3 h in medium containing 3 mM [2-3H]glycerol (0.5 Ci/ 
mol) and the additions indicated and incorporation of radiolabel into 
cell and medium TAG was determined as in [19]. Incorporation was 
linear during 3 h. 
2.5. Adipocyte isolation and determination of lipolysis 
Adipocytes were isolated from epididymal fat pads from 24 h fasted 
male Wistar rats (body wt 150-180 g) by collagenase digestion as in 
[20]. They were suspended in Krebs Ringer buffer containing 4% (w/v) 
defatted BSA to a cell volume of 6% (v/v). Adipocytes were preincu-
bated without or with etomoxir for 30 min, washed and resuspended 
to 6% (v/v). Adipocyte suspension (200 ul) was added to 200 |il of 
Krebs Ringer buffer containing 4% (w/v) BSA and the additions in-
dicated. After 10 min incubation in a shaking water bath at 37°C, 200 
ul of medium was deproteinized with 40 ul of ice-cold 10% (w/v) 
perchloric acid for determination of glycerol [20]. Results are ex-
pressed as nmol glycerol formed/min per unit volume of packed cells. 
3. Results and discussion 
When hepatocytes were incubated without exogenous FA 
for 24 h, the cellular TAG content declined from 80 nmol/mg 
to 48 nmol/mg in incubations without inhibitor and to 57-59 
nmol/mg in incubations with 5-50 |0.M etomoxir (Table 1). 
This inhibition of depletion of endogenous TAG stores by 
7?S-etomoxir was associated with increased TAG secretion 
at low [etomoxir] (1-10 uM) but with inhibition of secretion 
at 50 u,M etomoxir. Ketogenesis was progressively inhibited 
with increasing [etomoxir] up to a maximum of 50% indicat-
ing that in the absence of exogenous FA, ketone bodies are 
formed in part from endogenous FA presumably derived from 
TAG stores. The D-3-hydroxybutyrate/acetoacetate ratio was 
decreased by etomoxir indicating a more oxidised mitochon-
drial NADH/NAD redox state. 
To investigate the mechanism involved in the decreased 
depletion of TAG stores we determined the effects of RS-
etomoxir on the incorporation of [3H]glycerol in cellular 
and secreted TAG (Table 2). Low concentrations of RS-eto-
moxir (1-5 u\M) increased glycerol incorporation into cellular 
but not in secreted TAG with a net increase in glycerol incor-
poration into total TAG suggesting increased esterification. 
However, 100 |J.M etomoxir caused a net decrease in glycerol 
incorporation into total TAG, suggesting either inhibition of 
esterification or inhibition of lipolysis of endogenous TAG 
with consequent decreased availability of FA for esterifica-
tion. The demonstration of both stimulation and inhibition 
of [3H]glycerol incorporation into TAG is consistent with pre-
vious studies using other P-oxidation inhibitors (POCA and 
TDGA) which reported either inhibition of esterification [21] 
or increased esterification (and increased secretion) because of 
inhibition of P-oxidation [8,12]. 
To investigate the mechanisms of the opposite effects of low 
and high concentrations of etomoxir we used the R- and S-
enantiomers of etomoxir, because the inhibition of (3-oxida-
tion [15] but not the inhibition of FA and cholesterol biosyn-
thesis is specific for the i?-enantiomer [14]. We confirmed that 
only .R-etomoxir inhibited ketogenesis (Table 3). Surprisingly 
however, both enantiomers lowered the D-3-hydroxybutyrate/ 
acetoacetate ratio indicating that this is not simply due to 
inhibition of P-oxidation. Only the 7?-enantiomer increased 
secretion and cellular TAG at low concentrations (10 ufVl). 
However, both enantiomers inhibited TAG secretion at 100 
uM (Table 3). Incorporation of [3H]glycerol into total TAG 
was increased (P<0.05) by 1 uM and 10 uM i?-etomoxir 
(control, 3261 ±203; 1 uM, 4361 ±452; 10 uM, 4291 ±447 
dpm/well, means ± S.E.M., n = A) but not by S-etomoxir (1 
uM, 3144 ±452; 10 uM, 3329 ±757). 
These results suggest that the effects that are specific for low 
concentrations of the J?-enantiomer (increased TAG secretion, 
increased incorporation of [2-3H]glycerol into total TAG and 
decreased depletion of endogenous TAG) are secondary to 
inhibition of P-oxidation. By contrast, the inhibition of 
TAG secretion (Table 1) and net esterification (Table 2) by 
100 uM J?5-etomoxir are at least in part due to a mechanism 
that is independent of inhibition of P-oxidation since they are 
also elicited by the S-enantiomer. Since the inhibition of es-
terification by high [etomoxir] is not associated with increased 
depletion of cellular TAG, etomoxir may have an additional 
inhibitory effect on lipolysis and indirectly decrease esterifica-
Table 2 
Effect of PS-etomoxir on incorporation of [2-3H]glycerol into TAG 
[Etomoxir] [3H]Glycerol incorporated into triacylglycerol 
(uM) (dpm/well) 
0 
1 
5 
10 
50 
100 
Secreted 
358 ± 76 
296 ±81 
295 ±105 
296 ±109 
251 ±116 
187 ±77 
Cellular 
2878 ±399 
4169±399b 
4025 ± 345b 
3631 ±549 
3077 ±323 
2603 ±307 
Total 
3216 ±441 
4465±447b 
4319±400b 
3926 ±609 
3327 ±344 
2789±324a 
Hepatocytes were incubated for 3 h with the concentrations of RS-
etomoxir indicated plus 3 mM [2-3H]glycerol (0.5 Ci/mol) as described 
in Section 2. Incorporation of glycerol into cellular and secreted TAG 
is expressed as dpm/well. Values are means± S.E.M. (n = 4). Statistics: 
aP < 0.05, bP < 0.005, relative to respective control. 
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Table 3 
Effect of R- and S-etomoxir on TAG metabolism in hepatocytes 
Additions Ketones formed D-3-Hydroxybutyrate/ 
(nmol/mg protein) acetoacetate 
Triacylglycerol (nmol/mg protein) 
Secreted Cellular Total 
Control 498 ± 55 0.5710.03 38 ±6 48±2 5±5 
i?-etomoxir 
1 uM 
10 uM 
100 uM 
5-etomoxir 
1 itM 
10 uM 
100 uM 
311 ±44b 
274±35b 
255 ±32b 
490 ±56 
497 ± 62 
518±65 
0.48 ± 0.05a 
0.41 ± 0.02" 
0.42±0.06a 
0.53 ±0.04" 
0.52±0.04a 
0.44±0.05a 
52±7 
50±8 a 
13±3 a 
38 ±5 
34±8 
24 +4a 
55±4 
57±4 a 
61±5 a 
48 ±3 
52±2 
47 ±3 
107 ±9 a 
107± l l a 
74±3 a 
86 ±7 
84±9 
70±5 b 
Hepatocytes were incubated for 24 h with the concentrations of R- and S-etomoxir indicated. Ketone body (acetoacetate+3-hydroxybutyrate) 
formation is expressed as nmol/mg protein. Cellular and secreted TAG is expressed as nmol/mg protein. Cellular TAG content at the start of 
experiment was 80 ±4 nmol/mg protein. Values are means± S.E.M. (n = 4). Statistics: aP<0.05, bP<0.005 relative to respective control. 
tion of glycerol to TAG because of decreased availability of 
FA. 
The effect of etomoxir on lipolysis was determined in iso-
lated rat adipocytes from glycerol release as glycerol formed 
during hydrolysis of TAG is not further metabolised (Table 
4). iJS-etomoxir did not affect lipolysis in the absence of ad-
enosine deaminase. However, it inhibited the stimulated rate 
by 20% at 100 uM. 
It is noteworthy that the effects of etomoxir on adipocytes 
were determined in the presence of 4% BSA, whereas the 
experiments on hepatocytes were without albumin, and bind-
ing of etomoxir to albumin has been reported [23]. In addi-
tional experiments on hepatocytes where the effects of eto-
moxir on (3-oxidation were determined in both the absence 
and presence of 4% BSA, the sensitivity to etomoxir was 
greater in the absence of albumin (70% inhibition at 0.2 U.M 
etomoxir [22]) than in 4% BSA (70% inhibition at 10 uM 
etomoxir, results not shown), suggesting that the free [eto-
moxir] in the adipocyte experiments was much lower (about 
50-fold) than in the hepatocyte experiments. This may ac-
count for the apparently lower sensitivity in adipocytes com-
pared with hepatocytes. 
4. Conclusions 
This study shows that low and high etomoxir concentra-
tions have opposite effects on TAG metabolism in hepato-
Table 4 
Effect of .RS-etomoxir on the rate of lipolysis in adipocytes 
Addition Rate of lipolysis 
.RS-etomoxir 
0 uM 
1 |xM 
10 uM 
100 uM 
Basal rate 
158 ±44 
151 ±54 
150 ±41 
141 ±30 
Stimulated rate 
(+adenosine deaminase) 
925 ± 61 
892 ±60 
763 ± 84 
734±41 a 
Adipocytes were preincubated with 0-100 uM i?S'-etomoxir in the 
presence of 4% (w/v) defatted BSA for 30 min. Lipolysis was meas-
ured over a 10 min incubation in the absence or presence of adenosine 
deaminase with the additions indicated. The rate of lipolysis is ex-
pressed as nmol of glycerol released/min per ml packed cell volume. 
Results are means± S.E.M. for 4 experiments (8 animals). Statistics: 
aP<0.05. 
cytes. Low concentrations increase FA esterification and 
TAG secretion and inhibit TAG depletion by inhibition of 
(3-oxidation and diversion of FA to esterification. An addi-
tional inhibitory effect on hepatocyte lipolysis at low [etomox-
ir] cannot be excluded. High concentrations of etomoxir in-
hibit lipolysis, esterification and TAG secretion. These effects 
are not enantiomer-specific but were not associated with cy-
totoxic effects (as determined from release of lactate dehydro-
genase, results not shown). The metabolic effects of (3-oxida-
tion inhibitors have been investigated mainly in hepatocytes 
and muscle. In the perfused rat heart etomoxir was reported 
to inhibit lipolysis as a result of inhibition of P-oxidation [24]. 
However the effects of p-oxidation inhibitors on adipocytes 
have remained undocumented. The present study shows that 
etomoxir inhibits lipolysis in adipocytes and has biphasic ef-
fects on TAG secretion by hepatocytes. It is suggested that 
these effects of etomoxir on adipocytes and hepatocytes may 
explain the observations in vivo where chronic treatment with 
etomoxir was not associated with elevated plasma FA or 
TAG [4,9-11]. 
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